Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens

被引:51
作者
Ardeshna, KM [1 ]
Kakouros, N
Qian, W
Powell, MG
Saini, N
D'Sa, S
Mackinnon, S
Hoskin, PJ
Goldstone, AH
Linch, DC
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] UCL Hosp, Dept Haematol, London, England
[3] MRC, Clin Trials Unit, London, England
关键词
salvage chemotherapy; non-Hodgkin's lymphoma; Hodgkin's Lymphoma; autologous stem cell transplant; inadequate partial response;
D O I
10.1111/j.1365-2141.2005.05603.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to determine the outcome of patients with relapsed or refractory lymphoma who have an inadequate response to first- line salvage therapy (1 degrees ST) and who subsequently receive a second-line salvage regimen (2 degrees ST) with the intention of ultimately proceeding to high-dose therapy. The outcome of 57 patients [ Hodgkin's Lymphoma 17, histologically-aggressive non-Hodgkin's Lymphoma (NHL) 26, histologically-indolent NHL 14] who received more than one modality of conventional- dose salvage therapy was analysed. Sixteen patients had a partial response (PR) to 1 degrees ST, but subsequently received 2 degrees ST because the PR was judged to be inadequate ( iPR) because of persisting disease bulk or marrow infiltration. Of these 16 patients, 10 (63%) continued to respond to 2 degrees ST. Of the 15 patients who had stable disease following 1 degrees ST, 5 (33%) responded to 2 degrees ST. Only one of the 24 (4%) with progressive disease (PD) following 1 degrees ST, responded to 2 degrees ST. 25 of the 57 patients ultimately underwent stem cell transplantation. The 2-year progression-free survival (PFS) and the 3-year overall survival ( OS) for all patients was 24% and 31%, respectively. Long-term survival was highly dependent on response to 1 degrees ST (P = 0.0001); in patients with PD following 1 degrees ST, the PFS and OS at 3 years was only 4%. This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored.
引用
收藏
页码:363 / 372
页数:10
相关论文
共 33 条
[21]   BEAM CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKINS-LYMPHOMA [J].
MILLS, W ;
CHOPRA, R ;
MCMILLAN, A ;
PEARCE, R ;
LINCH, DC ;
GOLDSTONE, AH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :588-595
[22]   DEXA-BEAM IN PATIENTS WITH HODGKINS-DISEASE REFRACTORY TO MULTIDRUG CHEMOTHERAPY REGIMENS - A TRIAL OF THE GERMAN HODGKINS-DISEASE STUDY-GROUP [J].
PFREUNDSCHUH, MG ;
RUEFFER, U ;
LATHAN, B ;
SCHMITZ, N ;
BROSTEANU, O ;
HASENCLEVER, D ;
HAAS, R ;
KIRCHNER, H ;
KOCH, P ;
KUSE, R ;
LOEFFLER, M ;
DIEHL, V .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :580-586
[23]   HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER FAILURE OF CONVENTIONAL CHEMOTHERAPY IN ADULTS WITH INTERMEDIATE-GRADE OR HIGH-GRADE NON-HODGKINS-LYMPHOMA [J].
PHILIP, T ;
ARMITAGE, JO ;
SPITZER, G ;
CHAUVIN, F ;
JAGANNATH, S ;
CAHN, JY ;
COLOMBAT, P ;
GOLDSTONE, AH ;
GORIN, NC ;
FLESH, M ;
LAPORTE, JP ;
MARANINCHI, D ;
PICO, J ;
BOSLY, A ;
ANDERSON, C ;
SCHOTS, R ;
BIRON, P ;
CABANILLAS, F ;
DICKE, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (24) :1493-1498
[24]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].
PHILIP, T ;
GUGLIELMI, C ;
HAGENBEEK, A ;
SOMERS, R ;
VANDERLELIE, H ;
BRON, D ;
SONNEVELD, P ;
GISSELBRECHT, C ;
CAHN, JY ;
HAROUSSEAU, JL ;
COIFFIER, B ;
BIRON, P ;
MANDELLI, F ;
CHAUVIN, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545
[25]   The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups [J].
Prince, HM ;
Imrie, K ;
Crump, M ;
Stewart, AK ;
Girouard, C ;
Colwill, R ;
Brandwein, J ;
Tsang, RW ;
Scott, JG ;
Sutton, DMC ;
Pantalony, D ;
Carstairs, K ;
Sutcliffe, SB ;
Keating, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :880-889
[26]   100 AUTOTRANSPLANTS FOR RELAPSED OR REFRACTORY HODGKINS-DISEASE AND LYMPHOMA - VALUE OF PRETRANSPLANT DISEASE STATUS FOR PREDICTING OUTCOME [J].
RAPOPORT, AP ;
ROWE, JM ;
KOUIDES, PA ;
DUERST, RA ;
ABBOUD, CN ;
LIESVELD, JL ;
PACKMAN, CH ;
EBERLY, S ;
SHERMAN, M ;
TANNER, MA ;
CONSTINE, LS ;
DIPERSIO, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2351-2361
[27]   Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial [J].
Schmitz, N ;
Pfistner, B ;
Sextro, M ;
Sieber, M ;
Carella, AM ;
Haenel, M ;
Boissevain, F ;
Zschaber, R ;
Müller, P ;
Kirchner, H ;
Lohri, A ;
Decker, S ;
Koch, B ;
Hasenclever, D ;
Goldstone, AH ;
Diehl, V .
LANCET, 2002, 359 (9323) :2065-2071
[28]   High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial [J].
Schouten, HC ;
Qian, W ;
Kvaloy, S ;
Porcellini, A ;
Hagberg, H ;
Johnsen, HE ;
Doorduijn, JK ;
Sydes, MR ;
Kvalheim, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3918-3927
[29]   Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma.: Results of a single-centre study of 65 patients [J].
Soussain, C ;
Souleau, B ;
Gabarre, J ;
Zouabi, H ;
Sutton, L ;
Boccaccio, C ;
Albin, N ;
Charlotte, F ;
Merle-Béral, H ;
Delort, J ;
Binet, JL ;
Leblond, V .
LEUKEMIA & LYMPHOMA, 1999, 33 (5-6) :543-550
[30]   High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation [J].
Sweetenham, JW ;
Carella, AM ;
Taghipour, G ;
Cunningham, D ;
Marcus, R ;
Della Volpe, A ;
Linch, DC ;
Schmitz, N ;
Goldstone, AH .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3101-3109